v3.26.1
Discontinued Operations - Reconciliation of Discontinued Operations (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Costs and expenses:        
Net income from discontinued operations, net of tax $ 12,716 $ 342,629 $ 11,324 $ 333,458
Discontinued Operations Disposed of by Sale        
Discontinued Operations        
Net revenue 12,824 23,094 11,925 55,228
Costs and expenses:        
Cost of goods sold   6,548 55 25,897
Research and development 10 440 10 162
Selling, general and administrative (213) 2,027 (163) 9,483
Total costs and expenses (203) 9,015 (98) 35,542
Income from operations 13,027 14,079 12,023 19,686
Interest expense   (487)   (3,484)
Gain (Loss) on Sale Transactions, net (311) 339,102 (699) 339,102
Loss on debt extinguishment   (10,286)   (10,286)
Other income (expense), net   221   (11,560)
Net income from discontinued operations before income taxes 12,716 342,629 11,324 333,458
Net income from discontinued operations, net of tax 12,716 342,629 11,324 333,458
Discontinued Operations Disposed of by Sale | YUSIMRY immunology franchise        
Discontinued Operations        
Net revenue     2 43
Discontinued Operations Disposed of by Sale | CIMERLI ophthalmology franchise        
Discontinued Operations        
Net revenue $ 1,383 $ (96) $ 1,329 $ 533